Literature DB >> 29549512

Catheter ablation versus medical therapy for patients with persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized controlled trials.

Chen Chen1,2, Xinbin Zhou1, Min Zhu1, Shenjie Chen1, Jie Chen1, Hongwen Cai1, Jin Dai1, Xiaoming Xu1, Wei Mao3.   

Abstract

PURPOSE: The superiority of catheter ablation (CA) for persistent (and long-standing persistent) atrial fibrillation (AF) is currently not well defined. We performed a meta-analysis of randomized controlled trials (RCTs) to assess the clinical outcomes of CA compared with medical therapy in persistent AF patients.
METHODS: We systematically searched PubMed, EMBASE, the Cochrane Library, and clinicaltrials.gov for RCTs comparing CA with medical therapy in patients with persistent AF. For CA vs medical rhythm control, the primary outcome was freedom from atrial arrhythmia. For CA vs medical rate control, the primary outcome was the change in the left ventricular ejection fraction (LVEF).
RESULTS: Eight studies with a total of 809 patients were included in the final analysis. Compared with medical rhythm control, CA was superior in achieving freedom from atrial arrhythmia (RR 2.08, 95% CI [1.67, 2.58]; P < 0.00001). Similar result was found in CA arm without antiarrhythmic drug use after operation (RR 1.82, 95%CI [1.33, 2.49]; P = 0.0002). CA was also superior in reducing the probability of cardioversion (RR 0.59, 95%CI [0.46, 0.76]; P < 0.0001) and hospitalization (RR 0.54, 95%CI [0.39, 0.74]; P = 0.0002). Compared with the medical rate control in persistent AF patients with heart failure (HF), CA significantly improved the LVEF (MD 7.72, 95%CI [4.78, 10.67]; P < 0.00001) and reduced Minnesota Living with Heart Failure Questionnaire scores (MD 11.1395% CI [2.52-19.75]; P = 0.01).
CONCLUSIONS: CA appeared to be superior to medical therapy in persistent AF patients and might be considered as a first-line therapy for some persistent AF patients especially for those with HF.

Entities:  

Keywords:  Catheter ablation; Medical therapy; Meta-analysis; Persistent atrial fibrillation

Mesh:

Substances:

Year:  2018        PMID: 29549512     DOI: 10.1007/s10840-018-0349-8

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  29 in total

1.  Circumferential pulmonary-vein ablation for chronic atrial fibrillation.

Authors:  Hakan Oral; Carlo Pappone; Aman Chugh; Eric Good; Frank Bogun; Frank Pelosi; Eric R Bates; Michael H Lehmann; Gabriele Vicedomini; Giuseppe Augello; Eustachio Agricola; Simone Sala; Vincenzo Santinelli; Fred Morady
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

Review 2.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

3.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas; Stefan Agewall; John Camm; Gonzalo Baron Esquivias; Werner Budts; Scipione Carerj; Filip Casselman; Antonio Coca; Raffaele De Caterina; Spiridon Deftereos; Dobromir Dobrev; José M Ferro; Gerasimos Filippatos; Donna Fitzsimons; Bulent Gorenek; Maxine Guenoun; Stefan H Hohnloser; Philippe Kolh; Gregory Y H Lip; Athanasios Manolis; John McMurray; Piotr Ponikowski; Raphael Rosenhek; Frank Ruschitzka; Irina Savelieva; Sanjay Sharma; Piotr Suwalski; Juan Luis Tamargo; Clare J Taylor; Isabelle C Van Gelder; Adriaan A Voors; Stephan Windecker; Jose Luis Zamorano; Katja Zeppenfeld
Journal:  Eur J Cardiothorac Surg       Date:  2016-09-23       Impact factor: 4.191

4.  Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study).

Authors:  Giuseppe Stabile; Emanuele Bertaglia; Gaetano Senatore; Antonio De Simone; Franco Zoppo; Giovanni Donnici; Pietro Turco; Pietro Pascotto; Massimo Fazzari; Dino Franco Vitale
Journal:  Eur Heart J       Date:  2005-10-07       Impact factor: 29.983

5.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.

Authors:  Oussama M Wazni; Nassir F Marrouche; David O Martin; Atul Verma; Mandeep Bhargava; Walid Saliba; Dianna Bash; Robert Schweikert; Johannes Brachmann; Jens Gunther; Klaus Gutleben; Ennio Pisano; Dominico Potenza; Raffaele Fanelli; Antonio Raviele; Sakis Themistoclakis; Antonio Rossillo; Aldo Bonso; Andrea Natale
Journal:  JAMA       Date:  2005-06-01       Impact factor: 56.272

6.  A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial).

Authors:  Ross J Hunter; Thomas J Berriman; Ihab Diab; Ravindu Kamdar; Laura Richmond; Victoria Baker; Farai Goromonzi; Vinit Sawhney; Edward Duncan; Stephen P Page; Waqas Ullah; Beth Unsworth; Jamil Mayet; Mehul Dhinoja; Mark J Earley; Simon Sporton; Richard J Schilling
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-01-01

Review 7.  Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis.

Authors:  Saurav Chatterjee; Partha Sardar; Edgar Lichstein; Debabrata Mukherjee; Shamik Aikat
Journal:  Pacing Clin Electrophysiol       Date:  2012-09-14       Impact factor: 1.976

8.  A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure.

Authors:  David G Jones; Shouvik K Haldar; Wajid Hussain; Rakesh Sharma; Darrel P Francis; Shelley L Rahman-Haley; Theresa A McDonagh; S Richard Underwood; Vias Markides; Tom Wong
Journal:  J Am Coll Cardiol       Date:  2013-03-07       Impact factor: 24.094

9.  Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy.

Authors:  Giovanni B Forleo; Massimo Mantica; Lucia De Luca; Roberto Leo; Luca Santini; Stefania Panigada; Valerio De Sanctis; Augusto Pappalardo; Francesco Laurenzi; Andrea Avella; Michela Casella; Antonio Dello Russo; Francesco Romeo; Gemma Pelargonio; Claudio Tondo
Journal:  J Cardiovasc Electrophysiol       Date:  2008-09-03

10.  All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study.

Authors:  Tommy Andersson; Anders Magnuson; Ing-Liss Bryngelsson; Ole Frøbert; Karin M Henriksson; Nils Edvardsson; Dritan Poçi
Journal:  Eur Heart J       Date:  2013-01-14       Impact factor: 29.983

View more
  7 in total

1.  Action potential shortening rescues atrial calcium alternans.

Authors:  Giedrius Kanaporis; Zane M Kalik; Lothar A Blatter
Journal:  J Physiol       Date:  2018-12-05       Impact factor: 5.182

Review 2.  Management of Atrial Fibrillation in Patients with Heart Failure: Time to Implement Ablation Control.

Authors:  Alex Baher; Nassir F Marrouche
Journal:  Curr Cardiol Rep       Date:  2019-02-21       Impact factor: 2.931

3.  Utilization and Complications of Catheter Ablation for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy.

Authors:  Guy Rozen; Gabby Elbaz-Greener; Ibrahim Marai; Nizar Andria; Seyed Mohammadreza Hosseini; Yitschak Biton; E Kevin Heist; Jeremy N Ruskin; Yulia Gavrilov; Shemy Carasso; Diab Ghanim; Offer Amir
Journal:  J Am Heart Assoc       Date:  2020-06-23       Impact factor: 5.501

4.  Meta-Analysis of Catheter Ablation versus Medical Therapy for Heart Failure Complicated with Atrial Fibrillation.

Authors:  Xi Zhu; Yingbiao Wu; Zhongping Ning
Journal:  Cardiol Res Pract       Date:  2021-12-06       Impact factor: 1.866

5.  Biomarkers as predictors of recurrence of atrial fibrillation post ablation: an updated and expanded systematic review and meta-analysis.

Authors:  Vennela Boyalla; Leanne Harling; Alice Snell; Ines Kralj-Hans; Ana Barradas-Pires; Shouvik Haldar; Habib R Khan; John G F Cleland; Thanos Athanasiou; Sian E Harding; Tom Wong
Journal:  Clin Res Cardiol       Date:  2022-01-09       Impact factor: 6.138

6.  Comparison of co-administration of amiodarone and rivaroxaban to co-administration of dronedarone and rivaroxaban for hemorrhage risks after atrial fibrillation ablation.

Authors:  Peng Zhang; Maojing Wang; Wenheng Liu; Pin Sun; Shanglang Cai; Yaqi Pan; Qing Zhao
Journal:  J Interv Card Electrophysiol       Date:  2022-01-20       Impact factor: 1.759

7.  Methodological and Clinical Heterogeneity and Extraction Errors in Meta-Analyses of Catheter Ablation for Atrial Fibrillation in Heart Failure.

Authors:  Milton Packer
Journal:  J Am Heart Assoc       Date:  2019-10-18       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.